Enhua Pharmaceutical: Announcement on the Reform of the Board of Supervisors and the Election of Employee Representative Directors
Securities code: 002262 Securities abbreviation: Enhua Pharmaceutical Announcement number: 2025-061
Jiangsu Enhua Pharmaceutical Co., Ltd.
Announcement on the Reform of the Board of Supervisors and the Election of Employee Representative Directors
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and are jointly and severally responsible for any false records, misleading statements or major omissions in the announcement.
1. Reform of the Board of Supervisors
In accordance with the provisions of the "Company Law of the People's Republic of China" (hereinafter referred to as the "Company Law"), the "Transitional Arrangements Related to the Implementation of Supporting Institutions and Rules of the New Company Law" and the "Guidelines on the Articles of Association of Listed Companies (Revised in 2025)" and the "Shenzhen Stock Exchange Stock Listing Rules" and other relevant laws, regulations and normative documents, Jiangsu Enhua Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") in December 2025 At the fifth meeting of the seventh board of directors and the fifth meeting of the seventh board of supervisors held on March 3, the "Proposal on Cancellation of the Board of Supervisors, Change of Business Scope, Increase of Board of Directors, Amendment of Articles of Association, and Registration of Industrial and Commercial Changes" were reviewed and approved respectively. The company plans to cancel the board of supervisors and have no supervisors. The above matters have been reviewed and approved at the company's 2025 second extraordinary general meeting of shareholders held on December 19, 2025. The company's board of supervisors has stopped performing its duties. Supervisors Mr. Wang Fengshou, Mr. Jia Xinglei and Mr. Qian Xiaochen were automatically dismissed from their positions in the company's seventh session of the supervisory board due to the adjustment of the company's governance structure. After their dismissal, Mr. Wang Fengshou and Mr. Qian Xiaochen no longer hold any positions in the company; Mr. Jia Xinglei continues to hold other positions in the company.
The original term of the supervisors of the above-mentioned personnel is to end on April 25, 2028. As of the disclosure date of this announcement, Mr. Wang Fengshou does not directly hold shares in the company, but holds 737,900 yuan of equity in the company's controlling shareholder Xuzhou Enhua Investment Co., Ltd. (accounting for 1.61% of the registered capital). There is no related relationship between Mr. Wang Fengshou and the actual controller of the company, nor with other directors, senior managers or shareholders holding more than 5% of the company's shares. Mr. Jia Xinglei does not directly hold shares in the company, but holds 298,600 yuan of equity in the company's controlling shareholder Xuzhou Enhua Investment Co., Ltd. (accounting for 0.65% of the registered capital). There is no related relationship between Mr. Jia Xinglei and the actual controller of the company, nor with other directors, senior managers or shareholders holding more than 5% of the company's shares. Mr. Qian Xiaochen does not directly hold the company's shares, but holds 824,095 yuan of equity in the company's controlling shareholder Xuzhou Enhua Investment Co., Ltd. (accounting for 1.80% of the registered capital). There is no related relationship between Mr. Qian Xiaochen and the actual controller of the company, nor any related relationship with other directors, senior managers or shareholders holding more than 5% of the company's shares.
Mr. Wang Fengshou, Mr. Jia Xinglei and Mr. Qian Xiaochen have no commitments that should be performed but have not been performed.
Mr. Wang Fengshou, Mr. Jia Xinglei and Mr. Qian Xiaochen worked diligently and diligently during their tenure. The company expresses its sincere gratitude to all of them for their contributions to the company during their tenure as supervisors!
2. Election of employee representative directors
In accordance with the provisions of the "Company Law", "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 1 - Standardized Operations of Main Board Listed Companies" and "Guidelines on the Articles of Association of Listed Companies" and other relevant laws and regulations, the company held the Employee Representative Conference 2025 on December 19, 2025 At the second meeting of the year, after discussion and voting by the employee representatives present at the meeting, the meeting elected Mr. Jia Xinglei (please see the attachment for resume details) as the employee representative director of the company's seventh session of the Board of Directors, with a term starting from the date of review and approval by the employee representative conference to the expiration date of the company's seventh session of the Board of Directors. Mr. Jia Xinglei was changed from a non-employee representative supervisor of the seventh board of supervisors to an employee representative director of the seventh board of directors.
Mr. Jia Xinglei complies with the employment conditions stipulated in the "Company Law of the People's Republic of China", "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 1 - Standardized Operation of Main Board Listed Companies" and the "Articles of Association". After the election, the number of directors on the company's board of directors will be 10. Among them, the total number of directors who concurrently hold senior management positions and directors who are employee representatives does not exceed one-half of the company's total directors, which is in compliance with relevant laws, regulations and the provisions of the Articles of Association.
Announcement is hereby made.
Board of Directors of Jiangsu Enhua Pharmaceutical Co., Ltd.
December 19, 2025
Attachments:
Mr. Jia Xinglei, born in July 1969, Chinese nationality, no right of overseas residence, member of the Communist Party of China, graduated from Changzhou Chemical School of Jiangsu Province. From August 1989 to present, he has served as laboratory technician at the Research Institute of Xuzhou No. 3 Pharmaceutical Factory, technician of No. 2 Workshop, deputy director and director of No. 3 Pharmaceutical Factory, director of No. 3 Pharmaceutical Factory, head of Jiawang Branch of Jiangsu Enhua Pharmaceutical Co., Ltd., and Xuzhou Model Worker from 1998 to 2000. He served as a supervisor of the Company from April 23, 2007 to December 19, 2025.
As of the disclosure date of this announcement, Mr. Jia Xinglei does not directly hold shares in the company, but holds 298,600 yuan of equity in the company's controlling shareholder Xuzhou Enhua Investment Co., Ltd. (accounting for 0.65% of the registered capital). There is no related relationship between Mr. Jia Xinglei and the actual controller of the company, nor with other directors, senior managers or shareholders holding more than 5% of the company's shares. In the past three years, Mr. Jia Xinglei has not been punished by the China Securities Regulatory Commission and other relevant departments or disciplinary sanctions by the stock exchange; he has not been investigated by judicial authorities for suspected crimes or investigated by the China Securities Regulatory Commission for suspected violations of laws and regulations, and there has been no clear conclusion; he has not been investigated by the China Securities Regulatory Commission for illegal and untrustworthy information disclosure in the securities and futures markets. Publicly announced on the inquiry platform or included in the list of dishonest persons subject to enforcement by the people's court; there are no circumstances that prohibit nomination as a director as stipulated in Chapter 3, Section 2 of the "Guidelines for Standardized Operations"; his qualifications are in compliance with the Company Law, the Stock Listing Rules of the Shenzhen Stock Exchange, and the Self-Discipline Supervision Guidelines for Listed Companies of the Shenzhen Stock Exchange. No. 1 - Standardized Operations of Main Board Listed Companies" and "Articles of Association" and other relevant regulations.